Ethics Review Slows

Because the product is explicitly built from brain-cell research, regulators and bioethics groups may scrutinize consent, animal or human cell sourcing, welfare claims, and commercial use of neural tissue. This does not imply a systemic market shock, but it could slow biological computing investment and adoption.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.